On October 5, 2016 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, reported that it will present a poster presentation of updated data on its lead clinical program, an NY-ESO SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell therapy, in patients with synovial sarcoma at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2016 Congress (Press release, Adaptimmune, OCT 5, 2016, View Source;p=RssLanding&cat=news&id=2209585 [SID:SID1234515615]). This meeting will take place at the Bella Center exhibition center in Copenhagen, Denmark on October 7 through 11, 2016.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Sunday, October 9, 2016
Poster Presentation
Abstract number: 1075P
Title: "Open Label Non-Randomized Multi-Cohort Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO SPEAR T-cells in HLA-A*02+ Patients with Synovial Sarcoma"
Presentation Time: 13:00-14:00
Location: Hall E
The following synovial sarcoma cohorts will be reviewed in this poster presentation:
Cohort 1: Subjects with high NY-ESO-1 antigen expression and lymphodepletion with cyclophosphamide and fludarabine;
Cohort 2: Subjects with low NY-ESO-1 antigen expression and lymphodepletion with cyclophosphamide and fludarabine;
Cohort 3: Subjects with high NY-ESO-1 antigen expression and lymphodepletion with cyclophosphamide alone (no fludarabine);
Cohort 4: Subjects with high NY-ESO-1 antigen expression and lymphodepletion with a modified (lower) dose than Cohort 1 of cyclophosphamide and fludarabine.
These data follow presentations at the 2016 Annual American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Meeting, where we reported robust clinical responses in solid and hematologic tumors; durable persistence without the requirement for IL-2 support in vivo with cells detectable for up to three years; data showing that the incidence of cytokine release syndrome (CRS) appeared to be of lower frequency and severity compared to that reported with CD19 CAR-T therapy; and that our NY-ESO SPEAR T-cells have been generally well tolerated with common side effects including diarrhea, pyrexia, and fatigue. One fatal SAE of bone marrow failure was reported at ASCO (Free ASCO Whitepaper) in cohort 2 of our synovial sarcoma trial. Internal investigations have not identified a mechanism by which NY-ESO SPEAR T-cells may have caused bone marrow failure.
At ESMO (Free ESMO Whitepaper), the company will provide additional tolerability data of our NY-ESO SPEAR T-cells in patients with synovial sarcoma and an update on the benefit:risk profile in patients treated to date.
Adaptimmune’s SPEAR T-cell candidates are novel cancer immunotherapies that have been engineered to target and destroy cancer cells by strengthening a patient’s natural T-cell response. T-cells are a type of white blood cell that play a central role in a person’s immune response. Adaptimmune’s goal is to harness the power of the T-cell and, through its multiple therapeutic candidate, significantly impact cancer treatment and clinical outcomes of patients with solid and hematologic cancers.